Media coverage about Eli Lilly and (NYSE:LLY) has been trending somewhat positive on Monday, Accern reports. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eli Lilly and earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.8250897121605 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media headlines that may have effected Accern’s rankings:
- Health nominee reaped big earnings from drug industry tenure (marketbeat.com)
- Eli Lilly and Company (LLY) Given Consensus Recommendation of “Hold” by Analysts (americanbankingnews.com)
- Pharmaceutical Giant Eli Lilly Meets with Multicultural Groups (milwaukeecourieronline.com)
- Industry Group Rank Restrict Eli Lilly (LLY) Rating – Investorplace.com (investorplace.com)
- Lilly to Participate in Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference – PR Newswire (press release) (prnewswire.com)
A number of brokerages have commented on LLY. Credit Suisse Group downgraded shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and increased their price objective for the company from $84.23 to $88.00 in a research report on Tuesday, October 10th. Piper Jaffray Companies reissued a “buy” rating and issued a $103.00 price objective on shares of Eli Lilly and in a research report on Thursday, August 31st. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price objective on the stock in a research report on Thursday, October 26th. Jefferies Group LLC reissued a “buy” rating and issued a $89.00 price objective (down from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Finally, BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the company a “sell” rating in a research report on Wednesday, November 1st. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company’s stock. Eli Lilly and presently has a consensus rating of “Hold” and a consensus target price of $89.76.
Eli Lilly and (LLY) traded down $0.55 during mid-day trading on Monday, hitting $82.89. 4,097,800 shares of the stock traded hands, compared to its average volume of 3,707,715. Eli Lilly and has a one year low of $64.18 and a one year high of $89.09. The firm has a market cap of $91,269.77, a PE ratio of 20.27, a PEG ratio of 1.83 and a beta of 0.34. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03.
Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same quarter last year, the business earned $0.88 EPS. The business’s revenue was up 9.0% on a year-over-year basis. equities research analysts forecast that Eli Lilly and will post 4.21 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.51%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is 98.58%.
In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $81.06, for a total value of $14,590,800.00. Following the completion of the sale, the insider now owns 123,865,804 shares in the company, valued at $10,040,562,072.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. Insiders sold 772,003 shares of company stock valued at $64,837,441 in the last quarter. Company insiders own 0.20% of the company’s stock.
WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Eli Lilly and (LLY) Share Price” was first published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.truebluetribune.com/2017/11/20/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-eli-lilly-and-lly-share-price.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.